Effects of alendronate and vitamin D in patients with normocalcemic primary hyperparathyroidism.

What Was Tested

Researchers studied Vitamin D, K2, Magnesium and Zinc in the context of hyperparathyroidism in this randomized controlled trial publication.

The researchers treated 30 NPHPT postmenopausal women with alendronate/cholecalciferol (treated group) or vitamin D alone (control group).

Both treatments did not affect serum or urinary calcium.

Who Took Part

The study group was 30 women.

By PubMed's age tags, the people studied were middle-aged adults, women only.

The study was a prospective open label randomized trial comparing 15 postmenopausal women with NPHPT (PMW-NPHPT), treated with oral alendronate plus cholecalciferol (treated group) and 15 PMW-NPHPT treated only with cholecalciferol (control group).

How the Study Was Run

The design is described as randomized and open-label.

The women were allocated by chance, so the Vitamin D, K2, Magnesium and Zinc group and the comparison group should start out alike.

Everyone knew when Vitamin D, K2, Magnesium and Zinc was being given (open label), which is simpler to run but leaves more room for expectations to affect what is reported.

Safety of vitamin D was evaluated as secondary endpoint.

Blood samples were obtained at baseline and after 3, 6, and 12 months.

Bone turnover markers (BTM) were measured at baseline, 3, and 6 months, respectively.

What Was Measured

Normocalcemic primary hyperparathyroidism (NPHPT) is defined by normal serum calcium and consistently elevated PTH levels after ruling out the causes of secondary hyperparathyroidism.

The subject headings attached to it are Alendronate, Bone Density, Bone Density Conservation Agents, Calcium, Cholecalciferol, Drug Combinations and Femur.

What This Means in Plain Language

The paper is a randomized and open-label study of Vitamin D, K2, Magnesium and Zinc in 30 women in people with hyperparathyroidism.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

Its findings take up roughly 6 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2015 (Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA), a journal based in England.

More context: the Vitamin D, K2, Magnesium and Zinc compound page, Hyperparathyroidism research.